ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
ApplyBlast uses AI to match you with the right jobs, tailor your resume and cover letter, and apply automatically so you can land your dream job faster.
© All Rights Reserved. ApplyBlast.com
Synolo Therapeutics
Synolo Therapeutics is an early-stage biotechnology company pioneering the development of precision-targeted immunotherapies for cancer. The company utilizes computational protein design and proprietary technologies to build a pipeline of first-in-class multi-specific biologics with novel functionalities. Founded by pioneers in protein design, synthetic biology, and immunology, Synolo is committed to fostering a diverse and inclusive work environment.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1-10 employees
Founded
2023
Synolo Therapeutics is advancing a new class of logic-gated, conditionally-active immunotherapies for cancer and autoimmune disease. Launched by RA Ventures (the venture-focused division of RA Capital Management) and leveraging a proprietary discovery platform, the company is rapidly building a pipeline of differentiated candidates that promise to be highly effective and safer than the current standard of care.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Synolo Therapeutics.
Synolo Therapeutics didn’t post a salary, so this is our estimate from similar listings.
56% above the average for this role